Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 9/20 | 0.58 |
| ▸ | MMP2 | P08253 | 9/20 | 0.58 |
| ▸ | MMP13 | P45452 | 6/20 | 0.58 |
| ▸ | MMP3 | P08254 | 5/20 | 0.58 |
| ▸ | MMP1 | P03956 | 4/20 | 0.58 |
| ▸ | MMP7 | P09237 | 4/20 | 0.58 |
| ▸ | ADAMTS4 | O75173 | 4/20 | 0.49 |
| ▸ | MMP8 | P22894 | 1/20 | 0.46 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3612014 | 0.90 | MMP9 (0.54) | MMP9MMP2MMP13MMP3MMP1 | |
| SCHEMBL28753604 | 0.90 | MMP9 (0.54) | MMP9MMP2MMP13MMP3MMP1 | |
| SCHEMBL3620408 | 0.88 | MMP9 (0.47) | MMP9MMP2MMP13MMP3MMP1 | |
| SCHEMBL3103313 | 0.86 | MMP2 (0.77) | MMP9MMP2MMP13MMP3MMP1 | |
| SCHEMBL3617858 | 0.86 | MMP2 (0.77) | MMP9MMP2MMP13MMP3MMP1 | |
| SCHEMBL3617088 | 0.84 | MMP2 (0.56) | MMP9MMP2MMP13MMP3MMP1 | |
| SCHEMBL27612016 | 0.76 | MMP13 (0.49) | MMP9MMP2MMP13MMP3MMP1 | |
| SCHEMBL1655649 | 0.76 | MMP9 (0.69) | MMP9MMP2MMP13MMP3MMP1 | |
| SCHEMBL4428929 | 0.74 | MMP2 (1.00) | MMP9MMP2MMP13MMP3MMP1 | |
| SCHEMBL3599190 | 0.74 | MMP2 (1.00) | MMP9MMP2MMP13MMP3MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130324558-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | AERPIO THERAPEUTICS INC. (US) | 2013-12-05 | — | — | US | claimed |
| US-20130096140-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | AERPIO THERAPEUTICS INC. (US) | 2013-04-18 | — | — | US | claimed |
| US-20100016336-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | EyePoint Pharmaceuticals, Inc. | 2010-01-21 | — | — | US | claimed |
| US-20080108631-A1 | 4-{2-[2-(tert-Butoxycarbonyl)-3-phenylpropanamido]-2-(4-ethylthiazol-2-yl)ethyl}phenylsulfamic acid; anticarcinogenic, antitumor, antidiabrtic agent; angiogenesis inhibitor; sarcoid, syphilis, Paget's disease, vein occlusion, artery occlusion, carotid obstructive disease, chronic uveitis/vitritis | THE PROCTER & GAMBLE COMPANY (US) | 2008-05-08 | — | — | US | claimed |
| EP-3323815-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | Aerpio Therapeutics, Inc. (US) | 2018-05-23 | — | — | EP | disclosed |
| EP-2592072-A2 | Human protein tyrosine phosphatase inhibitors and their use | Warner Chilcott Company, LLC (PR) | 2013-05-15 | — | — | EP | disclosed |
| US-20100137298-A1 | Biaryl Sulfonamides and Methods for Using Same | WYETH (US) | 2010-06-03 | — | — | US | disclosed |
| EP-1692124-B1 | BIARYL SULFONAMIDES AS MMP INHIBITORS | WYETH CORP (US) | 2008-10-15 | — | — | EP | disclosed |
| US-7420001-B2 | Biaryl sulfonamides and methods for using same | WYETH (US) | 2008-09-02 | — | — | US | disclosed |
| EP-1692124-A1 | BIARYL SULFONAMIDES AS MMP INHIBITORS | Wyeth (US) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005061477-A1 | BIARYL SULFONAMIDES AS MMP INHIBITORS | WYETH (US) | 2005-07-07 | — | — | WO | disclosed |
| US-20050143422-A1 | Biaryl sulfonamides and methods for using same | WYETH (US) | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096140-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | PTPRCAP, PTPRC, PPP5C | MMP9 1800/4885MMP2 424/4885MMP13 1250/4885 |
| US-20100016336-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | PTPRCAP, PTPRC, PPP5C | MMP9 1800/4885MMP2 424/4885MMP13 1250/4885 |
| US-20100137298-A1 | Biaryl Sulfonamides and Methods for Using Same | STS, MMP3, AADAC | MMP9 14/4885MMP2 5/4885MMP13 13/4885 |
| US-20050143422-A1 | Biaryl sulfonamides and methods for using same | STS, MMP3, AADAC | MMP9 14/4885MMP2 5/4885MMP13 13/4885 |
| US-20080108631-A1 | 4-{2-[2-(tert-Butoxycarbonyl)-3-phenylpropanamido]-2-(4-ethylthiazol-2-yl)ethyl}phenylsulfamic acid; anticarcinogenic, antitumor, antidiabrtic agent; angiogenesis inhibitor; sarcoid, syphilis, Paget's disease, vein occlusion, artery occlusion, carotid obstructive disease, chronic uveitis/vitritis | VASP, DUSP15, PPP5C | MMP9 4355/4885MMP2 2643/4885MMP13 2380/4885 |
| US-20130324558-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | PTPRCAP, PTPRC, PPP5C | MMP9 1800/4885MMP2 424/4885MMP13 1250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.